HK2 and laryngeal squamous cell carcinoma: While the clinical applicability of these findings is yet to be determined, one study suggested miR-125a as a promising molecular target for laryngeal squamous cell carcinoma (LSCC) on the basis that miR-125a suppresses LSCC progression through targeting of HK2 both in vitro and in vivo analysis (Sun et al., 2017).